Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Healius Limited ( (AU:HLS) ) has provided an update.
Healius Limited has secured a contract with the Australian Department of Defence to supply private pathology services to the Australian Defence Force (ADF). This contract, which begins on December 1, 2025, and spans an initial five-year period, with potential extensions, is valued at approximately $60 million. The agreement will enhance pathology access for ADF personnel through Healius’s extensive national network of laboratories and collection centers, including those in regional and rural areas. The contract emphasizes Healius’s modern digital solutions, which aim to improve service delivery for both patients and doctors, thereby strengthening the company’s industry positioning and stakeholder relationships.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is one of Australia’s leading healthcare companies, providing specialty pathology services across the nation through a network of centers and over 8,000 employees. The company is dedicated to delivering quality, affordable, and accessible healthcare to all Australians.
YTD Price Performance: -2.20%
Average Trading Volume: 2,741,680
Technical Sentiment Signal: Sell
Current Market Cap: A$711.6M
See more insights into HLS stock on TipRanks’ Stock Analysis page.